These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 8167332

  • 1. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M.
    Blood; 1994 May 01; 83(9):2428-35. PubMed ID: 8167332
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS.
    N Engl J Med; 1993 Feb 18; 328(7):453-9. PubMed ID: 8421474
    [Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
    Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, Kogenate Post-Marketing Surveillance Study Group.
    Int J Hematol; 2003 Dec 18; 78(5):467-74. PubMed ID: 14704043
    [Abstract] [Full Text] [Related]

  • 5. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.
    Lusher J, Abildgaard C, Arkin S, Mannucci PM, Zimmermann R, Schwartz L, Hurst D.
    J Thromb Haemost; 2004 Apr 18; 2(4):574-83. PubMed ID: 15102011
    [Abstract] [Full Text] [Related]

  • 6. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V.
    Haemophilia; 2015 Nov 18; 21(6):791-8. PubMed ID: 26010678
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A, Komrska V, Jansen M, Laguna P.
    Haemophilia; 2011 May 18; 17(3):399-406. PubMed ID: 21118334
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.
    Taki M, Fukutake K, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Arai M, Takagi H, Uchikawa H, Engl W, Shirahata A.
    Int J Hematol; 2019 Jan 18; 109(1):70-78. PubMed ID: 30043332
    [Abstract] [Full Text] [Related]

  • 16. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, sippet study group.
    J Thromb Haemost; 2018 Jan 18; 16(1):39-43. PubMed ID: 29080391
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J, Refacto St Louis Study Group.
    Haemophilia; 2005 Sep 18; 11(5):444-51. PubMed ID: 16128886
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ, Sidonio RF, O'Day K, Runken MC, Meyer K, Spears J.
    J Med Econ; 2018 Aug 18; 21(8):762-769. PubMed ID: 29681200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.